跳至主要内容
临床试验/NCT02048345
NCT02048345Unknown不适用

Gastrointestinal Behavior of Posaconazol in Healthy Volunteers

KU Leuven1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
发起方
KU Leuven
入组人数
10
试验地点
1
主要终点
Concentration-time profile in stomach and small intestine for posaconazol

研究概览

简要总结

The aim of this study is to understand the behavior of posaconazol gives as a suspension and solution in the gastrointestinal tract in human volunteers. The investigators know that supersaturation for this compound can be achieved by the influence of the gastrointestinal tract: The acid environment of the stomach creates a optimized environment for the basic compound to reach a high solubility, while the neutral environment of the small intestine creates a low solubility environment for the compound. The transit from stomach to small intestine gives the opportunity for the drug to create a supersaturated solution. Giving the drug as a solution to the healthy volunteer makes sure that precipitation is not occurring in the stomach and that precipitation has to happen in the small intestine. After all, supersaturation is a state that is not thermodynamic stable and always will want to precipitate. Giving the drug as a suspension to the healthy volunteers, can make it possible that still some particles of the drug are not in dissolution and that those particles will flow to the small intestine where other particles easily can bind to. This will make that almost the whole supersaturated solution is immediately precipitated.

The investigators want to give the suspension by the authorized drug called Noxafil. On the other hand an aqueous solution will be made by adjusting the pH to 1.2 (which is conform with the pH of the stomach) and given to the volunteers by the stomach catheter. This 2 formulations will be tested in a fasted state and a fed state (by giving 2 Ensure plus shakes to the volunteers before the experiment starts). After intake of the formulation, gastric and duodenal fluids will be aspirated by the catheters and analyzed at their laboratory. So the four conditions the investigators want to study are:

  1. 10 mL Suspension of posaconazol (Noxafil 40mg/mL) together with a glass of 240 mL water in a fasted state
  2. 250 mL solution of posaconazol, by dissolving 2.6 mL autohorized suspension (Noxafil) in 247 mL water, adjusted to pH 1.2 by hydrochloric acid given to the volunteer in a fasted state.
  3. 10 mL Suspension of posaconazol (Noxafil 40mg/mL) together with a glass of 240 mL water in a fed state (by giving 20 minute before intake of the formulation, 2 ensure plus shakes)
  4. 250 mL solution of posaconazol, by dissolving 2.6 mL autohorized suspension (Noxafil) in 247 mL water, adjusted to pH 1.2 by hydrochloric acid given to the volunteer in a fed state (by giving 20 minute before intake of the formulation, 2 ensure plus shakes).

By getting more knowledge about the behavior of posaconazol (interplay supersaturation / precipitation) more insights can be achieved for the development of supersaturating drug delivery systems.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • 18-40 years Healthy volunteers

排除标准

  • disease Hiv, Hepatitis B, Hepatitis C Pregnant Drug abuse

研究组 & 干预措施

Suspension, fasted state

Experimental

Suspension Noxafil will be administered in the fasted state to the volunteers.

干预措施: Suspension Fasted State (Drug)

Suspension, with sugar (delay gastric emptying)

Experimental

Suspension will be co-administered with glucose to delay the gastric emptying time

干预措施: Suspension Fed State (Drug)

Solution, fasted state

Experimental

A solution (by acidifying the suspension in water to pH 1.2) will be administered to healthy volunteers in a fasted state.

干预措施: Solution Fasted State (Drug)

Solution, with sugar (delaying gastric emptying)

Experimental

A solution of posaconazol (by acidifying the suspension in water to pH 1.2) will be administered together with sugar to delay the gastric emptying.

干预措施: Solution Fed State (Drug)

结局指标

主要结局

Concentration-time profile in stomach and small intestine for posaconazol

时间窗: These concentrations will be measured for 4 hours, together by taking blood samples to see how the drug will be transported to the blood circulation (PK profile for 48 hours)

次要结局

未报告次要终点

研究者

发起方
KU Leuven
申办方类型
Other
责任方
Principal Investigator
主要研究者

Bart Hens

Pharmacist

KU Leuven

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Gastrointestinal behavior of posaconazol in healthy human volunteersSuspension: 105 mg posaconazol (2.6 ml Noxafil): 1)with 250 ml water 2)with 250 ml sparkling water 3)with 5 lumps of sugar, dissolved in 250 ml water 3)with 5 lumps of sugar, dissolved in 250 ml of sparkling water. Solution: 105 mg dissolved posaconazol (via Noxafil) by acidification of HCl until pH 1.2: 1)with 250 ml water 2)with 250 ml sparkling water 3)with 5 lumps of sugar, dissolved in 250 ml water 3)with 5 lumps of sugar, dissolved in 250 ml of sparkling water.
EUCTR2013-002836-26-BEKU Leuven - Drug Delivery & Disposition10
进行中(未招募)
1 期
Exploring how the tablet Noxafil reacts in the human body after oral intake•Administering one tablet of Noxafil with a glass of 240 ml of water•Administering four tablets of Noxafil with a glass of 240 ml of water•Administering one tablet of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)•Administering four tablets of Noxafil with a glass of 240 ml of water, prior to the intake of 400 ml Ensure plus (liquid meal)
EUCTR2015-002703-28-BEKU Leuven - Drug Delivery & Disposition5
招募中
4 期
Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell TransplantsPosaconazolePharmacokineticsInvasive CandidiasesInvasive AspergillosisInvasive MycosisProphylaxisFungal Infection
NCT03717623Melbourne Health100
已完成
1 期
Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)Fungal Infection
NCT02387983Merck Sharp & Dohme LLC65
已完成
1 期
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)Neutropenia
NCT02452034Merck Sharp & Dohme LLC118